KVUE
Kenvue
Stock NYSE – Stock Market Prices, News & Analysis
Kenvue Inc is a company specialized in the manufacturing and marketing of everyday health and wellness products.
Kenvue
KVUE
Kenvue Inc is a company specialized in the manufacturing and marketing of everyday health and wellness products.
Price history of Kenvue
Price history of Kenvue
Performance & Momentum
Kenvue beats estimates on key segment growth
Kenvue Inc. (KVUE) reported Q4 and full-year 2025 results that surpassed expectations, with sales growth across all segments and adjusted EPS exceeding consensus. Strong performance in the Self Care and Essential Health categories was highlighted, although the Beauty segment needs to focus on premiumization and product innovation. Several analysts, including Barclays, raised their price targets, reflecting moderate optimism about the stock's medium-term potential.
Strategic Analysis
Kenvue • 2026
Kenvue Inc positions itself as a major player in the consumer health sector, focused on widely consumed hygiene and wellness products. Its strategy is based on leveraging recognized brands and efficient distribution to maintain its market share in a competitive environment. The preparation of its quarterly results will be a key point for measuring its ability to recover its trajectory after several periods of underperformance.
Strengths
- Diversified portfolio of widely recognized products
- Established position in a defensive sector resilient to economic cycles
- Ability to capitalize on sustainable wellness and hygiene trends
Weaknesses
- Marked negative stock performance over the medium and long term
- Weak growth momentum in an intensely competitive context
Momentum
Kenvue's momentum shows an overall degraded trend, reflected by recent negative performances despite a favorable sector. The upcoming publication of fourth-quarter results represents a strategic event that could provide visibility on the continuation or not of operational recovery.
Similar stocks to Kenvue
Recent News
Kenvue
Kenvue Readies Q4 Earnings Release
2 months agoKenvue is set to report its quarterly results, with analysts expecting a low double-digit decline in earnings. This outlook indicates margin pressures and a possible upcoming stock adjustment, although the current daily drop of -0.94% remains moderate and stable. The situation highlights challenges faced in the consumer healthcare sector, particularly with over-the-counter products.
KVUE Among Preferred S&P 500 Dividend Aristocrats Before 2026
3 months agoThe article highlights that amid potential broad sell-offs, investors are advised to focus on S&P 500 Dividend Aristocrats, including KVUE. These stocks are valued for their stable yields and strong capacity to generate significant passive income, underpinning sustained market interest despite expected volatility.
Kenvue Price Targets Cut Despite Moderate Optimism
5 months agoKenvue (KVUE) faces lowered price targets from major banks like Jefferies (from $25 to $23) and Deutsche Bank (from $20 to $18) due to macroeconomic headwinds affecting the consumer healthcare sector and recent weakness in retail trends. Despite these downward revisions, analysts maintain a moderately optimistic stance with Buy or Hold ratings, highlighting potential for a future rebound. This reflects heightened caution around the stock, anticipating a disappointing third quarter that may weigh on short-term investor confidence.
Wall Street Steady Ahead of Powell's Rate Speech
6 months agoThe U.S. market, including Kenvue, remained mostly stable as investors awaited Jerome Powell's first address since the Fed resumed rate cuts. Despite a notable 2% drop, Kenvue's reaction appears to reflect profit-taking rather than a lasting downward trend. Caution prevails ahead of clear signals on monetary policy.
Take control
of your investments
Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.
- Real-time multi-portfolio tracking
- AI analysis of your positions
- Counter your cognitive biases
